within Pharmacolibrary.Drugs.ATC.H;

model H05AA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.36,
    Cl             = 0.26166666666666666,
    adminDuration  = 600,
    adminMass      = 8e-05,
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Abaloparatide is a synthetic analog of human parathyroid hormone-related peptide (PTHrP) and acts as an anabolic agent for the treatment of osteoporosis in postmenopausal women at high risk of fracture. It is approved for use in several regions including the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy postmenopausal women following subcutaneous administration of 80 micrograms abaloparatide.</p><h4>References</h4><ol><li><p>Merlotti, D, et al., &amp; Gennari, L (2019). Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. <i>Expert opinion on pharmacotherapy</i> 20(7) 805–811. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2019.1583208&quot;>10.1080/14656566.2019.1583208</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30856013/&quot;>https://pubmed.ncbi.nlm.nih.gov/30856013</a></p></li><li><p>Miller, PD, et al., &amp; Mitlak, B (2021). Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density. <i>Clinical drug investigation</i> 41(3) 277–285. DOI:<a href=&quot;https://doi.org/10.1007/s40261-021-01008-7&quot;>10.1007/s40261-021-01008-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33638863/&quot;>https://pubmed.ncbi.nlm.nih.gov/33638863</a></p></li><li><p>Myers, JT, et al., &amp; Bilezikian, JP (2025). An oral robotic pill reliably and safely delivers teriparatide with high bioavailability in healthy volunteers: A phase 1 study. <i>British journal of clinical pharmacology</i> None –. DOI:<a href=&quot;https://doi.org/10.1002/bcp.70064&quot;>10.1002/bcp.70064</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40194767/&quot;>https://pubmed.ncbi.nlm.nih.gov/40194767</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end H05AA04;
